Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADVANCE AUTO PARTS INCAAP · Entity 4323 | Director | April 03, 2020 | April 06, 2020 |
| AUTOLIV INCALV · Entity 3593 | Director | September 15, 2026 | September 17, 2026 |
| Aon plcAON · Entity 2608 | Director | June 25, 2026 | June 29, 2026 |
| BIOGEN INC.BIIB · Entity 1675 | EVP, Tech, Bus. Sol & Corp Aff | February 28, 2017 | March 02, 2017 |
| PERRIGO Co plcPRGO · Entity 4516 | Director | May 14, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADVANCE AUTO PARTS INC
Report date April 03, 2020 · Filed April 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,445.476 |
Reported balance
After 2020-04-03 transaction · row 1
1 source rowRow 1 · 2020-04-03 · Grant · Acquired 14.955 · Balance 5,445.476 F1: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives.
AUTOLIV INC
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,425.1232 |
Reported balance
After 2026-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 10.5907 · Balance 1,425.1232 F1: Each RSU represents a contingent right to receive one share of ALV common stock. F2: Dividend equivalent rights accrued in the form of additional RSUs. Per the award agreement, cash dividends with a record date on or after the grant date and paid on or before the vesting date yield additional RSUs subject to the same vesting schedule as the underlying RSUs. F3: The RSUs vest and convert to shares in one installment on the earlier of (a) the date of ALV's 2027 annual stockholder meeting, or (b) the one-year anniversary of May 7, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one share of ALV common stock.
F2: Dividend equivalent rights accrued in the form of additional RSUs. Per the award agreement, cash dividends with a record date on or after the grant date and paid on or before the vesting date yield additional RSUs subject to the same vesting schedule as the underlying RSUs.
F3: The RSUs vest and convert to shares in one installment on the earlier of (a) the date of ALV's 2027 annual stockholder meeting, or (b) the one-year anniversary of May 7, 2026.
Aon plc
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary StockSEC Table I · non-derivative | Direct | 2,605.735 |
Ending reported balance
After 2026-06-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-25 · Grant · Acquired 776 · Balance 2,791.97 F1: Class A Ordinary Shares granted annually to each non-employee director of Aon plc. In accordance with Irish law, reporting person agreed to pay the issuer the nominal value of US $0.01 per share issued to the reporting person. Row 2 · 2026-06-25 · Tax withholding · Disposed 186.235 · Balance 2,605.735 F2: Class A Ordinary Shares withheld by the issuer for payment of taxes in connection with the award. |
Filing footnotes · ownership attribution and instrument terms
F1: Class A Ordinary Shares granted annually to each non-employee director of Aon plc. In accordance with Irish law, reporting person agreed to pay the issuer the nominal value of US $0.01 per share issued to the reporting person.
F2: Class A Ordinary Shares withheld by the issuer for payment of taxes in connection with the award.
BIOGEN INC.
Report date February 28, 2017 · Filed March 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,752 |
Ending reported balance
After 2017-02-28 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-02-28 · Exercise / conversion · Acquired 570 · Balance 7,996 F1: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 2 · 2017-02-28 · Tax withholding · Disposed 253 · Balance 7,743 F1: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 3 · 2017-02-28 · Exercise / conversion · Acquired 1,494 · Balance 9,237 F2: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Row 4 · 2017-02-28 · Tax withholding · Disposed 485 · Balance 8,752 F2: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-02-22 | Direct | 6,886 |
Reported balance
After 2017-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-02-28 · Other · Disposed 1,198 · Balance 6,886 F3: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested. F4: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2018-02-23 | Direct | 2,092 |
Reported balance
After 2017-02-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-02-28 · Other · Disposed 952 · Balance 2,092 F3: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested. F5: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2018-02-23 | Direct | 1,522 |
Reported balance
After 2017-02-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-02-28 · Exercise / conversion · Disposed 570 · Balance 1,522 F1: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F6: This award was previously reported as covering 2,974 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F5: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-02-22 | Direct | 5,392 |
Reported balance
After 2017-02-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-02-28 · Exercise / conversion · Disposed 1,494 · Balance 5,392 F2: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F7: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F4: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017.
F2: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017.
F3: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested.
F4: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F5: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
F6: This award was previously reported as covering 2,974 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.
F7: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.
PERRIGO Co plc
Report date May 14, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 27,629 |
Ending reported balance
After 2025-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-05-14 · Exercise / conversion · Acquired 9,904 · Balance 32,383 Row 2 · 2025-05-14 · Tax withholding · Disposed 4,754 · Balance 27,629 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,305 |
Reported balance
After 2025-05-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-14 · Grant · Acquired 7,305 · Balance 7,305 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-05-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-14 · Exercise / conversion · Disposed 9,904 · Balance 0 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.
F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026.
F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ASPENTECH Corp
Report date May 16, 2022 · Filed May 18, 2022
Section 16 reporting ended · disclosed 2022-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-05-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-16 · Disposition to issuer · Disposed 2,229 · Balance 419 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the AspenTech common stock (other than certain excluded shares) automatically converted into the right to receive $87.69 in cash (the "Cash Consideration"), plus 0.42 of a validly issued, fully paid and nonassessable share of New AspenTech. Row 2 · 2022-05-16 · Disposition to issuer · Disposed 419 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F3: Reflects restricted stock units ("RSUs"). Each unvested RSU outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive an award of RSUs covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (x) the number of shares of AspenTech common stock underlying such AspenTech RSU award and (y) the sum of (i) 0.42 and (ii) the quotient obtained by dividing (xx) $87.69 by (yy) the volume-weighted average price per share of the New AspenTech common stock on Nasdaq during the five trading days after the Effective Time (the sum obtained under clause (y), the "Aspen Equity Award Exchange Ratio"). F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.00 · Expires 2030-07-21 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-16 · Disposition to issuer · Disposed 1,983 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F6: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F5: One third of the options granted at the exercise price of $97.00 will vest on the first anniversary of the grant and the remainder will vest in eight equal consecutive quarterly installments on the last business day of the quarter until fully vested. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $129.50 · Expires 2031-08-31 | Direct | 0 |
Reported balance
After 2022-05-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-16 · Disposition to issuer · Disposed 1,443 · Balance 0 F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech. F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time. F6: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent. F7: The option granted at the exercise price of $129.50 was fully vested on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 16, 2022, the closing of the transactions contemplated by the Transaction Agreement and Plan of Merger, dated as of October 10, 2021, as amended, among Aspen Technology, Inc. ("AspenTech"), Emerson Electric Co., Emersub CX, Inc., ("New AspenTech") and certain other parties, occurred, pursuant to which AspenTech merged with a wholly owned subsidiary of New AspenTech (the "Merger"). Pursuant to the Merger, AspenTech became a wholly owned subsidiary of New AspenTech.
F2: At the effective time of the Merger (the "Effective Time"), each outstanding share of the AspenTech common stock (other than certain excluded shares) automatically converted into the right to receive $87.69 in cash (the "Cash Consideration"), plus 0.42 of a validly issued, fully paid and nonassessable share of New AspenTech.
F3: Reflects restricted stock units ("RSUs"). Each unvested RSU outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive an award of RSUs covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (x) the number of shares of AspenTech common stock underlying such AspenTech RSU award and (y) the sum of (i) 0.42 and (ii) the quotient obtained by dividing (xx) $87.69 by (yy) the volume-weighted average price per share of the New AspenTech common stock on Nasdaq during the five trading days after the Effective Time (the sum obtained under clause (y), the "Aspen Equity Award Exchange Ratio").
F4: Each converted equity award described herein shall be subject to the same terms and conditions (including vesting and expiration schedule, as applicable) as applied to the corresponding AspenTech equity award as of immediately prior to the Effective Time.
F5: One third of the options granted at the exercise price of $97.00 will vest on the first anniversary of the grant and the remainder will vest in eight equal consecutive quarterly installments on the last business day of the quarter until fully vested.
F6: Each AspenTech stock option ("AspenTech Stock Option") outstanding immediately prior to the Effective Time was cancelled and assumed by New AspenTech and converted into the right to receive a New AspenTech stock option ("Converted Option") covering that number of shares of New AspenTech common stock, rounded down to the nearest whole share, equal to the product of (i) the number of shares of AspenTech common stock underlying the corresponding AspenTech Stock Option as of immediately prior to the Effective Time multiplied by (ii) the Aspen Equity Award Exchange Ratio. The exercise price applicable to each Converted Option shall be equal to (i) the exercise price per share of AspenTech common stock applicable to the corresponding AspenTech Stock Option as of immediately prior to the Effective Time divided by (ii) the Aspen Equity Award Exchange Ratio, rounded up to the nearest whole cent.
F7: The option granted at the exercise price of $129.50 was fully vested on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2020 Filed Jul 24, 2020 16:35 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,983 | $97.00 Strike: $97.00 | $192,351.00 |
DisclosureSEC source: 0001127602-20-022096 · form4.xml · derivative · entry 2 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,983 Underlying: Common Stock · 1,983 shares Expires 2030-07-21 F3 · derivative.exercise_date: One third of the options granted at the exercise price of $97.00 will vest on the first anniversary of the grant and the remainder will vest in eight equal consecutive quarterly installments on the last business day of the quarter until fully vested. Read SEC document |
| July 22, 2020 Filed Jul 24, 2020 16:35 UTC | ASPENTECH Corp AZPN · Entity 127212 | GrantCommon Stock | 1,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022096 · form4.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006 F1 · security: Each Restricted Stock Unit represents a contingent right to receive one share of Aspen Technology, Inc. common stock. One third of the Restricted Stock units will vest on the first anniversary of the grant date and the remainder will vest in eight equal consecutive quarterly installments on the last business day of the quarter until fully vested. F2 · price: The Restricted Stock Units were received as a grant for no consideration. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:40 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 6,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-20-000062 · wf-form4_158993519374084.xml · derivative · entry 3 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,054 shares Expires 2020-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2019. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:40 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 2,906 | $52.76 | $153,320.56 |
DisclosureSEC source: 0001585364-20-000062 · wf-form4_158993519374084.xml · nonDerivative · entry 2 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,429 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:40 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 6,054 | $52.76 | $319,409.04 |
DisclosureSEC source: 0001585364-20-000062 · wf-form4_158993519374084.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2019. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:54 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 5,804 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-20-000054 · wf-form4_158923044858176.xml · derivative · entry 2 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,804 Underlying: Ordinary Shares · 5,804 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 7 May 2021. Read SEC document |
| April 03, 2020 Filed Apr 6, 2020 19:39 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 14.955 | $84.65 | $1,265.94 |
DisclosureSEC source: 0001158449-20-000096 · wf-form4_158620195836711.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,445.476 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 20:25 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1.905 | $159.42 | $303.70 |
DisclosureSEC source: 0001158449-20-000018 · wf-form4_157842869778581.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,430.521 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| October 04, 2019 Filed Oct 7, 2019 19:37 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1.898 | $159.94 | $303.57 |
DisclosureSEC source: 0001158449-19-000187 · wf-form4_157047704758678.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,428.616 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 19:17 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1.889 | $160.62 | $303.41 |
DisclosureSEC source: 0001158449-19-000147 · wf-form4_156269981821191.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,426.718 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| May 15, 2019 Filed May 16, 2019 17:38 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 994.67 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001158449-19-000105 · wf-form4_155802827501088.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,424.829 F1 · price: These deferred stock units, which will be converted to shares of issuer common stock at the time of distribution, were awarded under the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. These shares will vest on May 1, 2020 and will be distributed on a pro-rata basis if board service ends prior to the vesting date. Otherwise, these shares will be distributed to the reporting person at the end of the director's board service. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:02 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 3,971 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-19-000068 · wf-form4_155812333054539.xml · derivative · entry 4 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,971 shares Expires 2019-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2018. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:02 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 6,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-19-000068 · wf-form4_155812333054539.xml · derivative · entry 3 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,054 Underlying: Ordinary Shares · 6,054 shares Expires 2020-05-15 F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:02 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 1,907 | $49.55 | $94,491.85 |
DisclosureSEC source: 0001585364-19-000068 · wf-form4_155812333054539.xml · nonDerivative · entry 2 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,281 Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:02 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 3,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001585364-19-000068 · wf-form4_155812333054539.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2018. Read SEC document |
| April 05, 2019 Filed Apr 8, 2019 18:45 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1.379 | $176.78 | $243.78 |
DisclosureSEC source: 0001158449-19-000076 · wf-form4_155474913335355.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,430.159 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 20:31 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1.534 | $158.81 | $243.61 |
DisclosureSEC source: 0001158449-19-000015 · wf-form4_154689304536380.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,428.78 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 20:11 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1.468 | $165.83 | $243.44 |
DisclosureSEC source: 0001158449-18-000180 · wf-form4_153911589242670.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,427.246 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 18:17 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1.775 | $137.17 | $243.48 |
DisclosureSEC source: 0001158449-18-000140 · wf-form4_153124663362219.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,425.778 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:08 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionRestricted Stock Units · Derivative | 4,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-18-000041 · wf-form4_152849207547509.xml · derivative · entry 3 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,265 shares Expires 2018-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:08 UTC | PERRIGO Co plc PRGO · Entity 4516 | Tax withholdingOrdinary Shares | 2,048 | $73.22 | $149,954.56 |
DisclosureSEC source: 0001585364-18-000041 · wf-form4_152849207547509.xml · nonDerivative · entry 2 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,217 Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:08 UTC | PERRIGO Co plc PRGO · Entity 4516 | Exercise / conversionOrdinary Shares | 4,265 | $73.22 | $312,283.30 |
DisclosureSEC source: 0001585364-18-000041 · wf-form4_152849207547509.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on June 6, 2017. Read SEC document |
| May 29, 2018 Filed May 31, 2018 20:32 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001158449-18-000122 · wf-form4_152779872227449.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,424.003 F1 · price: These deferred stock units, which will be converted to shares of issuer common stock at the time of distribution, were awarded under the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. These shares will vest on May 29, 2019 and will be distributed on a pro-rata basis if board service ends prior to the vesting date. Otherwise, these shares will be distributed to the reporting person at the end of the director's board service. Read SEC document |
| May 15, 2018 Filed May 17, 2018 19:55 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 3,971 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-18-000031 · wf-form4_152658691567725.xml · derivative · entry 2 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,971 Underlying: Ordinary Shares · 3,971 shares Expires 2019-05-15 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| April 06, 2018 Filed Apr 16, 2018 19:37 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1.504 | $111.91 | $168.31 |
DisclosureSEC source: 0001158449-18-000078 · wf-form4_152390743404456.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,174.003 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 18:44 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1.499 | $112.18 | $168.16 |
DisclosureSEC source: 0001158449-18-000016 · wf-form4_151552344366747.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,172.499 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| October 06, 2017 Filed Dec 18, 2017 21:25 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 2 | $94.29 | $188.58 |
DisclosureSEC source: 0001158449-17-000208 · wf-form4_151363234449773.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,171 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| July 07, 2017 Filed Jul 10, 2017 20:47 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1 | $101.93 | $101.93 |
DisclosureSEC source: 0001158449-17-000142 · wf-form4_149971966023678.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,169 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 19:37 UTC | PERRIGO Co plc PRGO · Entity 4516 | GrantRestricted Stock Units · Derivative | 4,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001585364-17-000094 · wf-form4_149695064147850.xml · derivative · entry 2 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,265 Underlying: Ordinary Shares · 4,265 shares Expires 2018-06-06 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document |
| June 02, 2017 Filed Jun 5, 2017 20:06 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | PurchaseCommon Stock | 125 | $136.58 | $17,072.50 |
DisclosureSEC source: 0001158449-17-000131 · wf-form4_149669315482005.xml · nonDerivative · entry 2 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,168 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:06 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | PurchaseCommon Stock | 242 | $134.61 | $32,575.62 |
DisclosureSEC source: 0001158449-17-000131 · wf-form4_149669315482005.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,043 Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 20:21 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001158449-17-000123 · wf-form4_149634847662469.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,801 F1 · price: These deferred stock units, which will be converted to shares of issuer common stock at the time of distribution, were awarded under the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. These shares will vest on May 1, 2018 and will be distributed on a pro-rata basis if board service ends prior to the vesting date. Otherwise, these shares will be distributed to the reporting person at the end of the director's board service. Read SEC document |
| April 07, 2017 Filed Apr 10, 2017 20:52 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1 | $142.05 | $142.05 |
DisclosureSEC source: 0001158449-17-000092 · wf-form4_149185754858416.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,861 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,494 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · derivative · entry 8 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,392 Underlying: Common Stock · 1,494 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F7 · shares: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F7 · derivative.underlying_shares: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F7 · balance_after: This award was previously reported as covering 7,900 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 570 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · derivative · entry 7 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,522 Underlying: Common Stock · 570 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F6 · shares: This award was previously reported as covering 2,974 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F6 · derivative.underlying_shares: This award was previously reported as covering 2,974 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F6 · balance_after: This award was previously reported as covering 2,974 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 952 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · derivative · entry 6 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,092 Underlying: Common Stock · 952 shares Expires 2018-02-23 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested. F5 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,198 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · derivative · entry 5 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,886 Underlying: Common Stock · 1,198 shares Expires 2019-02-22 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number of shares that vested. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 485 | $287.63 | $139,500.55 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · nonDerivative · entry 4 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,752 F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · nonDerivative · entry 3 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 253 | $284.75 | $72,041.75 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · nonDerivative · entry 2 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,743 F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 570 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009807 · form4.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:26 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 5,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007114 · form4.xml · derivative · entry 1 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 Underlying: Common Stock · 5,100 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 21:22 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1 | $169.63 | $169.63 |
DisclosureSEC source: 0001158449-17-000010 · wf-form4_148408332430782.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,860 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:34 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 48 | $296.53 | $14,233.44 |
DisclosureSEC source: 0001127602-16-069152 · form4.xml · nonDerivative · entry 2 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,360 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 21:34 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 171 | $295.78 | $50,578.38 |
DisclosureSEC source: 0001127602-16-069152 · form4.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,408 Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:37 UTC | ADVANCE AUTO PARTS INC AAP · Entity 4323 | GrantCommon Stock | 1 | $148.13 | $148.13 |
DisclosureSEC source: 0001158449-16-000500 · wf-form4_147621824206458.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,859 F1 · shares: These shares of issuer common stock were acquired pursuant to a dividend reinvestment feature of the Advance Auto Parts, Inc. Deferred Stock Unit Plan for Non-Employee Directors and Selected Executives. Read SEC document |
| October 04, 2016 Filed Oct 5, 2016 20:24 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 262 | $311.94 | $81,728.28 |
DisclosureSEC source: 0001127602-16-064339 · form4.xml · nonDerivative · entry 1 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,579 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 21:02 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 380 | $313.00 | $118,940.00 |
DisclosureSEC source: 0001127602-16-064102 · form4.xml · nonDerivative · entry 4 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,841 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 21:02 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,280 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064102 · form4.xml · derivative · entry 6 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,266 Underlying: Common Stock · 2,280 shares Expires 2017-10-01 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 21:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,982 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064102 · form4.xml · derivative · entry 5 Karaboutis Adriana · CIK 0001619963 · EVP, Tech, Bus. Sol & Corp Aff 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,546 Underlying: Common Stock · 1,982 shares Expires 2017-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.